Moving Toward a Unified Global HIV/AIDS Agenda: Communities of Color in Crisis

  • Bisola Ojikutu
  • Jamal Harris


At the conclusion of 2007, UNAIDS and the World Health Organization (WHO) estimated that there were 33.2 million people living with HIV (PLWHA) worldwide.1 Since the first cases were identified more than 25 years ago, HIV infection has been reported in every region of the world. However, the most dire consequences of this disease have been manifested in resource-poor settings where health care infrastructure is suboptimal, access to education is minimal, and poverty is rampant. Over the course of the last 5 years, efforts have been initiated to mitigate the disparate impact that HIV has in these settings. Though universal access to treatment is an unmet and distant goal, antiretroviral therapy is now more widely available. In addition, there has been a decrease in the number of new HIV infections, primarily due to strides made in both prevention and access to effective care and treatment1

This chapter will focus on the HIV epidemic in three of the most resource-limited regions of the world: sub-Saharan Africa, the Caribbean, and Latin America. Each of these regions has been impacted by varying degrees by HIV/AIDS. Each faces ongoing challenges while combating the spread of infection and struggling to treat those who are already infected. However, progress has been made. Lessons that can be derived from the development of successful prevention interventions and from scale-up of treatment programs in these regions will be highlighted.


Male Circumcision Sexual Debut Female Condom Condom Usage Concurrent Partnership 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    UNAIDS. 2007 AIDS Epidemic Update. Available at: Accessed on June 30, 2008.
  2. 2.
    European Study Group on Heterosexual Transmission of HIV. Comparison of female to male and male to female transmission of HIV in 563 stable couples. BMJ. 1992;304:809–13.Google Scholar
  3. 3.
    Mastro TD, de Vincezzi I. Probabilities of sexual HIV transmission. AIDS. 1996;10 Suppl A:S75–82.PubMedCrossRefGoogle Scholar
  4. 4.
    Vittinghoff E, Douglas J, Judson F, et-al. Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Am J Epidemiol. 1999;150:306–11.PubMedCrossRefGoogle Scholar
  5. 5.
    Sa Z, Larsen U. Gender inequality increases women’s risk of hiv infection in Moshi, Tanzania. J Biosoc Sci. 2008;40:505–25. Epub 2007 Dec 19.PubMedCrossRefGoogle Scholar
  6. 6.
    Clark S. Early marriage and HIV risks in sub-Saharan Africa. Stud Fam Plann. 2004;35: 149–60.PubMedCrossRefGoogle Scholar
  7. 7.
    Report National HIV and Syphilis Prevalence Survey South Africa 2006 Department of Health South Africa, 2007. Available at: Accessed on June 30, 2008.
  8. 8.
    UNAIDS Fact Sheet: Sub-Saharan Africa. 2006. Available at: Accessed on June 30, 2008.
  9. 9.
    Mahomva A, Greby S, Dube, S, et-al. Sexually transmitted infections HIV prevalence and trends from data in Zimbabwe, 1997–2004. Sex Transm Infect. 2006;82 Suppl 1:i42–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Federal Ministry of Health Nigeria, 2005 Sentinel Survey. Available at: Accessed on: June 30, 2008.
  11. 11.
    Auvert B, Taljaard D, Lagarde E, et-al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005;2:e298.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Bailey RC, Moses S, Parker CB, et-al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomized controlled trial. Lancet. 2007;369:643–56.PubMedCrossRefGoogle Scholar
  13. 13.
    Gray RH, Kigozi G, Sirwadda D et-al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomized trial. Lancet. 2007;369:657–66.PubMedCrossRefGoogle Scholar
  14. 14.
    World Health Organization. Male circumcision for HIV prevention. Available at: Accessed on June 30, 2008.
  15. 15.
    Freeman EE, Weiss HA, Glynn JR, et-al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS. 2006;20:73–83.PubMedCrossRefGoogle Scholar
  16. 16.
    Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis. 2002;185:45–52.PubMedCrossRefGoogle Scholar
  17. 17.
    Celum CL. The interaction between herpes simplex virus and human immunodeficiency virus. Herpes. 2004;11 Suppl 1:36A–45A.PubMedGoogle Scholar
  18. 18.
    Weiss H. Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes. 2004;11 Suppl 1:24A–35A. Review.PubMedGoogle Scholar
  19. 19.
    Celum C, Wald A, Hughes J, et al. HSV-2 suppressive therapy for prevention of HIV acquisition: results of HPTN 039. 2008. Fifteenth Conference on Retroviruses and Opportunistic Infections, Boston, abstract 32LB.69.Google Scholar
  20. 20.
    Watson-Jones D, Rusizoka M, Weiss H, et al. Impact of HSV-2 suppressive therapy on HIV incidence in HSV-2 seropositive women: a randomised controlled trial in Tanzania. 2007. Abstract MOAC104. Fourth IAS Conference on HIV pathogensis, treatment and prevention 2007, Sydney, Australia.Google Scholar
  21. 21.
    Mastro TD, Satten GA, Nopkesorn T et-al. Probability of female-to-male transmission of HIV-1 in Thailand. Lancet.1994;343:204–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Halperin DT, Epstein H. Concurrent sexual partnerships help to explain Africa’s high HIV prevalence: implications for prevention. Lancet. 2004 Jul 3–9;364:4–6.PubMedCrossRefGoogle Scholar
  23. 23.
    CAREC. CAREC Surveillance Report Supplement, Vol. 23, Supplement 1; October 2003.Google Scholar
  24. 24.
    Allen CF, Edwards M, Williamson LM et-al. Sexually transmitted infection service use and risk factors for HIV infection among female sex workers in Georgetown, Guyana. J Acquir Immune Defic Syndr. 2006;43:96–101.PubMedCrossRefGoogle Scholar
  25. 25.
    UNAIDS Epidemic Update, December 2005. Available at: Accessed on June 30, 2008.
  26. 26.
    Caistor N, Henrys JH, Street A. HIV and AIDS in Haiti. Catholic Institute for International Relations, UK; 2008:6–17.Google Scholar
  27. 27.
    Cohen J. HIV/AIDS: Latin America & Caribbean. HAITI: making headway under hellacious circumstances. Science. 2006;313:470–3.Google Scholar
  28. 28.
    Gaillard EM, Boulos LM, Andre Cayemettes MP, et-al. Understanding the reasons for decline of HIV prevalence in Haiti. Sex Transm Inf. 2006;82 Suppl 1:i14–20.CrossRefGoogle Scholar
  29. 29.
    Hsieh YH, Arazoza H, Lee SM, et-al. Estimating the number of Cubans infected sexually by human immunodeficiency virus using contact tracing data. Int J Epi. 2002;31:679–683.CrossRefGoogle Scholar
  30. 30.
    Arazoza H, Joanes J, Lounes R, et-al.. The HIV/AIDS epidemic in Cuba: description and tentative explanation of its low HIV prevalence. BMC Infect Dis. 2007;7:130.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Cohen J. Cuba Increasing HIV Prevention Efforts Targeted at MSM, Health Officials Says. Available at: Accessed on June 30, 2008.
  32. 32.
    Aceijas C, Stimson GV, Hickman M, et-al. Global overview of injecting drug use and HIV infection among injecting drug users. AIDS. 2004;18:2295–303.PubMedCrossRefGoogle Scholar
  33. 33.
    Cohen J. HIV/AIDS: Latin America & Caribbean. Puerto Rico: rich port, poor port. Science. 2006;313:475–6.PubMedCrossRefGoogle Scholar
  34. 34.
    Berkman A, Garcia J, Munoz-Laboy M, et-al. A critical analysis of the Brazilian response to HIV/AIDS: lessons learned for controlling and mitigating the epidemic in developing countries. Am J Public Health. 2005;95:1162–72.PubMedCrossRefGoogle Scholar
  35. 35.
    Levi GC, Vitoria MA. Fighting against AIDS: the Brazilian experience. AIDS. 2002;16:2373–83.PubMedCrossRefGoogle Scholar
  36. 36.
    Okie S. Fighting HIV-Lessons from Brazil. NEJM. 2006;354:1977–81.PubMedCrossRefGoogle Scholar
  37. 37.
    Cohen J. HIV/AIDS: Latin America & Caribbean. Overview: the overlooked epidemic. Science. 2006;313:468–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Bronfman MN, Leyva R, Negroni MJ, et-al. Mobile populations and HIV/AIDS in Central America and Mexico: research for action. AIDS 2002;16 Suppl 3:S42–S49.PubMedCrossRefGoogle Scholar
  39. 39.
    Magis-Rodriguez C, Gayet C, Negroni M, et-al. Migration and AIDS in Mexico: an overview based on recent evidence. J Acquir Immune Defic Syndr. 2004;37 Suppl 4:S215–S226.PubMedCrossRefGoogle Scholar
  40. 40.
    The Global Fund to Fight HIV, TB and Malaria. Available at: Accessed on June 30, 2008.
  41. 41.
    World Health Organization. Progress on Global Access to HIV Antiretroviral Therapy: A Report on “3 by 5” and Beyond, March 2006. Available at: Accessed on July 20, 2008.
  42. 42.
    UNAIDS. Towards Universal Access: Scaling Up Priority HIV/AIDS Interventions in the Health Sector. 2008. Available at: Accessed on June 30, 2008.
  43. 43.
    President’s Emergency Plan for AIDS Relief. Available at: Accessed on June 30, 2008.
  44. 44.
    Steinbrook R. Providing antiretroviral therapy for HIV infection. NEJM. 2001;344:844–6.PubMedCrossRefGoogle Scholar
  45. 45.
    Drug Access: Clinton Foundation, Global Fund, World Bank, UNICEF Extend Low-Cost Generic AIDS Drug Prices to More Than 100 Countries. Available at: Accessed on July 4, 2008.
  46. 46.
    Ojikutu B, Jack C, Ramjee G, et-al. Provision of antiretroviral therapy in South Africa: unique challenges and remaining obstacles. J Infect Dis. 2007;196 Suppl 3:S523–27.PubMedCrossRefGoogle Scholar
  47. 47.
    Malawi: Health Worker Shortage a Challenge to AIDS Treatment. Accessed on: June 30, 2008.
  48. 48.
    Corbett EL, Marston B, Churchyard GJ, et-al. Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet 2006;367:926–37.PubMedCrossRefGoogle Scholar
  49. 49.
    Kline M. Perspectives on the pediatric HIV/AIDS pandemic: catalyzing access of children to care and treatment. Pediatrics. 2006;117:1388–93.PubMedCrossRefGoogle Scholar
  50. 50.
    Ferrandini L, Jeannin A, Pinoges L, et-al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet. 2006;367:1335–42.CrossRefGoogle Scholar
  51. 51.
    Brigido L, Rodrigues R, Vasseb J, et-al. CD4+ T-cell recovery and clinical outcome in HIV-1-infected patients exposed to multiple antiretroviral regimens: partial control of viremia is associated with favorable outcome. AIDS Patient Care STDS. 2004;18:189–98.PubMedCrossRefGoogle Scholar
  52. 52.
    Kilaru KR, Kumar A, Sippy N, et-al. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country. HIV Med. 2006;7:99–104.PubMedCrossRefGoogle Scholar
  53. 53.
    Braitstein P, Brinkhof MW, Dabis F, et-al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006;367:817–24.PubMedCrossRefGoogle Scholar
  54. 54.
    Dalal RP, Macphail C, Mqhayi M, et-al. Characteristics and outcomes of adult patients lost to follow-up at an antiretroviral treatment clinic in johannesburg, South Africa. J Acquir Immune Defic Syndr. 2008;47:101–7.PubMedCrossRefGoogle Scholar
  55. 55.
    Mills EJ, Nachega JB, Buchan I, et-al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA. 2006;296:679–90.PubMedCrossRefGoogle Scholar
  56. 56.
    Remien RH, Bastos FI, Jnr VT, et-al. Adherence to antiretroviral therapy in a context of universal access, in Rio de Janeiro, Brazil. AIDS Care. 2007;19:740–8.PubMedCentralPubMedCrossRefGoogle Scholar
  57. 57.
    Etard JF, Lanièce I, Fall MB, et-al. A 84-month follow up of adherence to HAART in a cohort of adult Senegalese patients. Trop Med Int Health. 2007;12:1191–8.PubMedCrossRefGoogle Scholar
  58. 58.
    Reddi A, Leeper SC. Antiretroviral therapy adherence in children: outcomes from Africa. AIDS. 2008;22:906–7.PubMedCrossRefGoogle Scholar
  59. 59.
    Ware NC, Wyatt MA, Bangsberg D. Examining theoretic models of adherence for validity in resource-limited settings. A heuristic approach. J Acquir Immune Defic Syndr. 2006;43 Suppl 1:S18–22.CrossRefGoogle Scholar
  60. 60.
    Hardon AP, Aukurt D, Comoro C, et-al. Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa. AIDS Care. 2007;19:658–65.PubMedCrossRefGoogle Scholar
  61. 61.
    Mbulaiteye SM, Mahe C, Whitworth JA, et-al. Declining HIV-1 incidence and associated prevalence over 10 years in a rural population in south-west Uganda: a cohort study. Lancet. 2002;360:41–6.PubMedCrossRefGoogle Scholar
  62. 62.
    Green EC, Halperin DT, Nantulya V, et-al. Uganda’s HIV prevention success: the role of sexual behavior change and the national response. AIDS Behav. 2006;10:335–46.PubMedCentralPubMedCrossRefGoogle Scholar
  63. 63.
    Slutkin G, Okware S, Naamara W, et-al. How Uganda reversed its HIV epidemic. AIDS Beh. 2006;10:351–60.CrossRefGoogle Scholar
  64. 64.
    Ukwuani FA, Tsui AO, Suchindran CM, et-al. Condom use for preventing HIV infection/AIDS in sub-Saharan Africa: a comparative multilevel analysis of Uganda and Tanzania. J Acquir Immune Defic Syndr. 2003;34:203–13.PubMedCrossRefGoogle Scholar
  65. 65.
    Wakabi W. Condoms still contentious in Uganda’s struggle over AIDS. Lancet 2006;367:1387–8.PubMedCrossRefGoogle Scholar
  66. 66.
    Cheluget B, Baltazar G, Orege P, et-al. Evidence for population level declines in adult HIV prevalence in Kenya. Sex Transm Inf. 2006;82:i21–i26.CrossRefGoogle Scholar
  67. 67.
    Gregson S, Garnett GP, Nyamukapa C, et-al. HIV decline associated with behavior change in eastern Zimbabwe. Science. 2006;311:664–66.PubMedCrossRefGoogle Scholar
  68. 68.
    Turner AN, Morrison CS, Padian NS, et-al. Men’s circumcision status and women’s risk of HIV acquisition in Zimbabwe and Uganda. AIDS. 2007;21:1779–89.PubMedCentralPubMedCrossRefGoogle Scholar
  69. 69.
    Williams B, Lloyd-Smith J, Hankins C, et-al. The potential impact of male circumcision on HIV in Sub-Saharan Africa. PLoS Med. 2006;3:e262.PubMedCentralPubMedCrossRefGoogle Scholar
  70. 70.
    Johnson KE, Quinn TC. Update on male circumcision: prevention success and challenges ahead. Cur Inf Dis Rep. 2008;10:243CrossRefGoogle Scholar
  71. 71.
    Kigozi G, Gray RH, Wawer MJ, et-al. The safety of adult male circumcision in HIV-infected and uninfected men in Rakai, Uganda. PLoS Med. 2008;5:e116.PubMedCentralPubMedCrossRefGoogle Scholar
  72. 72.
    Barbosa RM, Kalckman S, Berquo E, et-al. Notes on the female condom: experiences in Brazil. Int J STD AIDS. 2007;18:261PubMedCrossRefGoogle Scholar
  73. 73.
    Centers for Disease Control and Prevention. Introduction of routine HIV testing in prenatal care–Botswana, 2004. MMWR Mord Mort Weekly Rep. 2004;53:1083–86.Google Scholar
  74. 74.
    Creek TL, Ntumy R, Seipone K, et-al. Successful introduction of routine opt-out HIV testing in antenatal care in Botswana. J Acquir Immune Defic Syndr. 2007;45:102–7.PubMedCrossRefGoogle Scholar
  75. 75.
    Centers for Disease Control and Prevention (CDC) Increases in HIV diagnoses–29 States, 1999–2002. MMWR Morb Mortal Wkly Rep. 2003;52:1145–8.Google Scholar
  76. 76.
    Government of the District of Columbia DoHHAABoSaE. The District of Columbia HIV/AIDS Epidemiology Annual Report 2007.Google Scholar
  77. 77.
    Branson BM, Hansfield HH, Lampe MA, et-al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55:1–17.PubMedGoogle Scholar
  78. 78.
    Saag M. Opt-out testing: who can afford to take care of patients with newly diagnosed HIV infection? Clin Inf Dis. 2007;45 Suppl 4:S261–5.CrossRefGoogle Scholar
  79. 79.
    Behforouz H, Farmer P, Mukherjee J. From directly observed therapy to accompagnateurs: enhancing AIDS treatment outcomes in Haiti and in Boston. Clin Infect Dis. 2004;38 Suppl 5:S429–36.PubMedCrossRefGoogle Scholar
  80. 80.
    HIV vaccine failure prompts Merck to halt trial. Nature. 2007; 449: 390.Google Scholar
  81. 81.
    Padma TV. After microbicide failures, hope that antiviral approach will gel. Nat Med. 2008;14:354.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Bisola Ojikutu
    • 1
  • Jamal Harris
  1. 1.Massachusetts General Hospital, Office of International Programs, Division of AIDSHarvard Medical SchoolBostonUSA

Personalised recommendations